Physician profile
Robert Michael Williams
NPI 1033155874
$994.61
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $224 · 2021: $25.71 · 2022: $20.69 · 2023: $52.55 · 2024: $18.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $52.55 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $52.55 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $252.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $181.80 | 2019-2024 | Keytruda |
| Genzyme Corporation | $115.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $69.96 | 2019-2020 | |
| Tersera Therapeutics LLC | $63.67 | 2019-2023 | Quzyttir |
| Pfizer INC. | $61.91 | 2019-2020 | |
| Celgene Corporation | $42.71 | 2019 | |
| Gilead Sciences, INC. | $33.66 | 2019-2021 | |
| Seagen INC. | $27.61 | 2019 | |
| Amgen INC. | $25.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.40 | 2019 | |
| Eisai INC. | $19.69 | 2020 | |
| Genentech USA, INC. | $17.85 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $16.13 | 2019 | |
| Puma Biotechnology, INC. | $15.41 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $15.06 | 2020 | |
| Baxter Healthcare | $13.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.